Abbott Laboratories (ABT) Other Non Operating Income (2009 - 2026)

Abbott Laboratories has reported Other Non Operating Income for 18 years, with the latest figure at $134.0 million in Q2 2026.

• Quarterly Other Non Operating Income fell 2.19% year-over-year to $134.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $577.0 million (up 7.05% YoY) and the FY2025 annual result came in at -$5.9 billion, up 20.97% from the prior year.
• Other Non Operating Income slipped to $134.0 million in Q2 2026 per ABT's latest filing, from $159.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $176.0 million in Q2 2023 and troughed at -$10.0 million in Q2 2024.
• A 5-year average of $112.1 million and a median of $116.0 million in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income plunged 105.68% in 2024, then soared 1470.0% in 2025.
• Over 5 years, Other Non Operating Income stood at $68.0 million in 2022, then jumped by 60.29% to $109.0 million in 2023, then jumped by 41.28% to $154.0 million in 2024, then slipped by 12.99% to $134.0 million in 2025, then changed by 0.0% to $134.0 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $134.0 million, $159.0 million, and $134.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.